NCT03061955已完成不适用
Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 28
- 主要终点
- Number of participants with confirmed influenza infection as assessed by influenza rapid antigen A and B testing, nose swab.
研究概览
简要总结
The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years or older
- •Currently receiving immunotherapy with anti-PD-1 agents (Nivolumab or Pembrolizumab)
- •Have not received influenza vaccination prior to study entry date for the upcoming flu season 2016-2017
- •No previous contraindication to receiving influenza vaccination
- •Histologically proven cancer
- •Expected lifetime of at least 12 weeks
排除标准
- •Previous cancer
- •Autoimmune disease or immunosuppressive treatments
- •Corticosteroid treatment
- •Those who have a potential indication to change chemotherapy treatment in 42 days following start of treatment
- •History of clinically or virologically confirmed influenza infection in the previous six months
- •Previous contraindication to receiving influenza vaccination
- •Previous allergic/adverse reaction with influenza vaccination
- •Have received influenza vaccination prior to study entry date for upcoming 2016-2017 flu season
- •Positive anti influenza antibody titers as determined by the baseline blood determination (day 0)
结局指标
主要结局
Number of participants with confirmed influenza infection as assessed by influenza rapid antigen A and B testing, nose swab.
时间窗: October 1st 2016 to March 31st 2017
participants with confirmed influenza infection as assessed by influenza rapid antigen A and B testing, nose swab.
次要结局
- Number of participants with adverse events and grading of adverse event as measured by the adverse events toxicity scale.(October 1st 2016 to March 31st 2017)
- Number of participants requiring hospitalizations for adverse events or influenza infection.(October 1st 2016 to March 31st 2017)
- Number of participants with seroconversion as assessed by influenza A and B IgM and IgG titers.(October 1st 2016 to March 31st 2017)
研究者
相似试验
已完成
4 期
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)Rhinitis, Allergic, PerennialNCT00806754AstraZeneca340
进行中（未招募）
不适用
Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)EUCTR2014-004924-23-Outside-EU/EEASchering-Plough Research Institute, a Division of Schering Corporation875
已完成
3 期
Administration of Two Injections for Multiple Dupuytren's ContracturesDupuytren's ContractureNCT01407068Endo Pharmaceuticals60
已完成
1 期
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL PatientsChronic Myeloid LeukemiaNCT02253277Novartis Pharmaceuticals5
Unknown
3 期
Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal JunctionGastroesophageal Junction AdenocarcinomaNCT03986385Hebei Medical University180